The approval of TEPOXX in Japan marks another significant milestone in our mission to expand access to this critical ...
Tecovirimat did not improve time to lesion resolution compared with placebo in patients with mild to moderate mpox disease.
Scott Parker, Department of Molecular Microbiology & Immunology, Saint Louis University Health Sciences Center, St Louis, MO 63104, USA Lauren Handley, Department of Molecular Microbiology ...
Here we describe historical, current and future therapies to treat orthopoxvirus diseases. Scott Parker, Department of Molecular Microbiology & Immunology, Saint Louis University Health Sciences ...